English 
简体中文 Brivaracetam (BRV)
1) The main possible mechanism: Interaction with synaptic vesicle protein 2A (SV2A). It has a higher affinity than levetiracetam. In addition, it has been reported that it also has a certain blocking effect on sodium channels. However, some believe that brivaracetam had no added therapeutic benefit when co-administered with levetiracetam (refer to the 2021 version of the FDA instructions)
2) Therapeutic indications: Currently, the FDA has approved the treatment of focal-onset seizures in patients 1 month of age and older.
3) Warning: Except for those who are allergic to the drug and cannot be used, the others are not clear yet.
4) Dosage for children: Click to view the dosage for children of different ages and weights.
5) Major adverse reactions in children: In some cases, there will be drowsiness, dizziness, fatigue, nausea, vomiting, ataxia, behavior and emotional changes.
6) Interaction with other anti-epileptic drugs: Brivaracetam (reversible inhibitor of epoxy hydrolase) can significantly increase the concentration of carbamazepine epoxide (The carbamazepine epoxide plasma concentration increased up to nearly 200% at a brivaracetam dose of 100 mg twice daily, while carbamazepine can reduce the concentration of brivaracetam by about 25%), brivaracetam can increase the plasma concentration of phenytoin sodium by about 20%, and phenytoin sodium can reduce the plasma concentration of brivaracetam by about 20%, phenobarbital can also reduce the plasma concentration of brivaracetam by about 20%.
7) Interaction with non-anti-epileptic drugs: Rifampicin can reduce the concentration of brivaracetam by about 50%.